A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia

A. Rossi, D. Campo, M. C. Fortuna, V. Garelli, G. Pranteda, G. De Vita, L. Sorriso-Valvo, D. Di Nunno & M. Carlesimo


To link to this article: http://dx.doi.org/10.1080/09546634.2017.1341610

Accepted author version posted online: 12 Jun 2017.
Published online: 29 Jun 2017.

Submit your article to this journal

Article views: 56

View related articles

View Crossmark data
A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia

A. Rossi, D. Campo, M. C. Fortuna, V. Garelli, G. Pranteda, G. De Vita, L. Sorriso-Valvo, D. Di Nuncio and M. Carlesimo

ABSTRACT

Background: Androgenetic alopecia (AGA) is a common form of scalp hair loss that affects up to 50% of males between 18 and 40 years old. Several molecules are commonly used for the treatment of AGA, acting on different steps of its pathogenesis (Minoxidil, Finasteride, Serenoa repens) and show some side effects. In literature, on the basis of hypertrichosis observed in patients treated with analogues of prosta glandin PGF2α, it was supposed that prostaglandins would have an important role in the hair growth: PGE and PGF2α play a positive role, while PGD2 a negative one.

Objective: We carried out a pilot study to evaluate the efficacy of topical cetirizine versus placebo in patients with AGA. Patients and methods: A sample of 85 patients was recruited, of which 67 were used to assess the effectiveness of the treatment with topical cetirizine, while 18 were control patients.

Results: We found that the main effect of cetirizine was an increase in total hair density, terminal hair density and diameter variation from T0 to T1, while the vellus hair density shows an evident decrease. The use of a molecule as cetirizine, with no notable side effects, makes possible a good compliance by patients.

Conclusion: Our results have shown that topical cetirizine 1% is responsible for a significant improvement of the initial framework of AGA.

Materials and methods

A sample of 85 patients (both male and female aged between 20 and 65 years) was recruited, of which 67 were used to assess the effectiveness of the treatment with topical cetirizine, while 18 were control patients (both male and female aged between 22 and 60). All the patients were in good health conditions and with different grades of AGA (we used the Hamilton classification, modified in order to evaluate also the quantity of the hairs in the vertex). All patients were asked to fill out the informed consent.

The aim of our report was to evaluate the efficacy and tolerability of a galenic lotion composed of cetirizine 1%, 16% cyclo-silicone-pentamer, 96°C of ethyl alcohol applied once a day on the scalp. In order to perform the study, the patients were divided into two groups: the first one characterized by the use of topical cetirizine 1% (1 application/daily = 1 ml/daily) and the second one treated with placebo (16% cyclo-silicone-pentamer, 96°C of ethyl alcohol, 1 application/daily = 1 ml/daily). The exclusion criteria were: previous therapies for AGA, systemic diseases and pregnancy.
For each patient, we evaluated the following variables: total hair density \( (D) \), vellus hair density \( (VD) \), terminal hair density \( (TD) \) and diameter \( (d) \). We have defined as the vellus hairs as the hairs with a diameter \( <0.05 \text{ mm} \) and the terminal ones \( \geq 0.05 \text{ mm} \).

The first visit was performed at \( T_0 \) and was repeated after 6 months of treatment at \( T_1 \).

Macrophotographs at 20–70\( \times \) (Trichoscan Dermoscope Fotofinder\textsuperscript{®}) were performed to collect photographic reports. The final score was obtained by averaging the evaluation given by a group of expert dermatologists.

In Table 1, we show the results of analysis, in particular the mean and standard deviation of the parameters variation \( <|\Delta P |> \pm \sigma \) and of the variation normalized to the initial value \( <|\Delta P/P(T_0)|> \pm \sigma \), where \( P=D, DV, DT, d \).

### Results

In order to quantify the improvement of the estimated parameters, we compute the mean and standard deviation of variation \( <|\Delta P |> \pm \sigma > = <P(T_1) - P(T_0)> \), where \( T_1 \) and \( T_0 \) represent the times taken into account to compute the averaged parameter variations. After six months of treatment with cetirizine, the patients show an increase in the average \( <|\Delta D |> = 0.31 \) that represents \( <|\Delta D/ D(T_0) |> = 11\% \) variation relative to initial total density. This can be seen in Figure 1 where an evident improvement of total density is clearly visible. Similar results were obtained for the diameter (see Table 1) while for the terminal density we found a significant improvement of \( <|\Delta TD/ TD(T_0) |> = 18\% \). The vellus density shows a decrease in \( <|\Delta VD/VD(T_0) |> = 15\% \). On the contrary in the control group, we observed variations of 1\% for the total density and 3\% for the terminal density as shown in Table 2.

### Discussion

Androgenetic alopecia is a common form of scalp hair loss that affects up to 50\% of males between 18 and 40 years old. The onset of AGA is extremely variable and the physical aspect is characterized by progressive miniaturization of scalp hair follicles (1,2).

Up to date, the role of prostaglandins in AGA is rarely reported in literature.

Garza et al. found elevated levels of prostaglandin D2 synthase (PTGDS) at the mRNA and protein levels in bald human scalp tissue. Furthermore, Garza et al. provided functional data indicating that PGD2 and its no enzymatic metabolites, 15-

| Table 1. Results of analysis for patients treated with cetirizine. First column: total density, vellus density terminal density and diameter variation. For each parameter, the mean and standard deviation of variation and maximum value of the variation were normalized to the initial value. |
|----------------|----------------|----------------|----------------|----------------|
| \( <|\Delta D |> ±\sigma \) | \( <|\Delta VD |> ±\sigma \) | \( <|\Delta TD |> ±\sigma \) | \( <|\Delta d |> ±\sigma \) |
| 30.31 ± 4.21 | 9.14 ± 1.99 | 31.68 ± 3.74 | 3.30 ± 0.27 |
| \( [2.30, 142.90] \) | \( [0.5, 67.4] \) | \( [1.9, 105.2] \) | \( [0.7] \) |
| \( <|\Delta D/D(T_0)|> ±\sigma \) | \( <|\Delta VD/VD(T_0)|> ±\sigma \) | \( <|\Delta TD/TD(T_0)|> ±\sigma \) | \( <|\Delta d/d(T_0)|> ±\sigma \) |
| 0.11 ± 0.02 | 0.15 ± 0.02 | 0.18 ± 0.02 | 0.05 ± 0.01 |
| \( [0.01, 0.51] \) | \( [0.02, 0.69] \) | \( [0.01, 0.54] \) | \( [0.0, 0.1] \) |

| Table 2. Results of analysis for the control group. |
|----------------|----------------|----------------|----------------|----------------|
| \( <|\Delta D |> ±\sigma \) | \( <|\Delta VD |> ±\sigma \) | \( <|\Delta TD |> ±\sigma \) | \( <|\Delta d |> ±\sigma \) |
| 2.59 ± 0.55 | 0.59 ± 0.13 | 5.60 ± 1.39 | 1.83 ± 0.53 |
| \( [2.30, 5.90] \) | \( [0.20, 1.20] \) | \( [0.60, 14.40] \) | \( [0.5] \) |
| \( <|\Delta D/D(T_0)|> ±\sigma \) | \( <|\Delta VD/VD(T_0)|> ±\sigma \) | \( <|\Delta TD/TD(T_0)|> ±\sigma \) | \( <|\Delta d/d(T_0)|> ±\sigma \) |
| 0.01 ± 0.01 | 0.02 ± 0.01 | 0.03 ± 0.01 | 0.04 ± 0.01 |
| \( [0.00, 0.02] \) | \( [0.01, 0.04] \) | \( [0.00, 0.08] \) | \( [0.00, 0.12] \) |

**Figure 1.** Global photography of patients treated with cetirizine at \( T_0 \) (a, c, e, g) and at \( T_1 \) (b, d, f, h).
deoxy-Δ12,14-prostaglandin J2 (15-dPGJ2), inhibit hair growth in both mouse and human hair follicles. In addition, in mice and human models, hair growth inhibition requires the PGD(2) receptor G protein-coupled receptor 44 (GPR44), but not the PGD(2) receptor 1 (PTGDR) (6–8).

All these results implicate PGD2 in the pathogenesis of AGA and may suggest new receptor targets for its treatment. In fact, recent evidences highlighted a role for prostaglandins in regulating hair growth. For example, the PGF2α analogous latanoprost is Food and Drug Administration (FDA) approved and routinely used clinically to enhance hair growth of human eyelashes (9). PGE2 has been proposed to protect radiation-induced hair loss in mice and both PGE2 and PGF2α have been shown to enhance hair growth in mice. These studies confirm that prostaglandins are deregulated in AGA, the most common type of hair loss in men.

In front of these evidences, the aim of our study was that to evaluate the efficacy and tolerability of a topical lotion containing cetirizine 1% for the treatment of AGA in male and female patients. To our knowledge, this is the first report in literature that evaluates the efficacy of cetirizine in AGA.

Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist, widely used in daily practice. Charlesworth et al. showed that cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production. However, these effects apparently are not related to its anti-H1 activity (10).

Cetirizine hydrochloride is a racemic mixture composed of equal amounts of two enantiomers, R-levocetirizine and S-dextro cetirizine, which do not undergo interconversion and therefore maintain configuration stability in the body. Cetirizine has been shown to have highly favorable pharmacological properties. In particular, cetirizine is a zwitterion, with high binding to mainly serum albumin and low apparent volume of distribution, as well as low brain uptake, which are indicative of a low affinity for lean tissues such as the myocardium (thus low cardiototoxicity) and low/lack of sedative effects, respectively. Cetirizine has also been shown to be absorbed extensively and rapidly from the gut, leading to high bio-availability and rapid onset of action of the drug, and unlike many other second generation antihistamines, it does not undergo hepatic metabolism to any appreciable extent, but is excreted mostly unchanged in the urine, equally well in both healthy volunteers and patients with chronic liver disease. The lack of hepatic metabolism demonstrates a low potential for drug–drug interactions, which avoids any exaggerated pharmacological or toxicological effects with drugs that are subject to metabolism by P450 enzymes and to transmembrane transport. Similarly, H1 receptor binding studies have demonstrated that compared with many other commonly used second-generation H1 antihistamines, cetirizine has a relatively higher and more favorable affinity and selectivity for H1 receptors, which confers a more potent, faster onset and longer duration of action. Studies investigating the anti-inflammatory/anti-allergic effects of cetirizine have indicated that it may exhibit anti-inflammatory properties independent of its H1 effects (11).

According to reports about the effect of various types of prosta taglandins on hair follicle cycling, it has been showed that the E and F types (PGE and PGFα) stimulate the hair growth, while the D types (in particular PGD2) favor the progression of baldness (6). Indeed, PGD2 inhibits hair growth, favoring the miniaturization. In this regard, we can state that inhibition of PGD2 (as di-hydroxy testosterone) through the use of cetirizine is a further pathogenic clue in AGA, resulting to be a new and promising target treatment for AGA. Finally, the lower number of potential side effects if compared with other drugs commonly used for AGA, as minoxidil (often cause of hypertrichosis, contact allergic dermatitis, headache and hypotension), can promote a wider use of cetirizine in the future for the treatment of AGA.

Conclusions

The use of a molecule as cetirizine, with no notable side effects, makes possible a good compliance by patients. In fact, patients often alarmed by media campaigns, do not follow faithfully the therapy required by the physicians. It is therefore primarily the patient adherence to treatment, which obviously depends on the effectiveness of the drug. Another advantage of this therapy is the possible use in female compared to other drugs yet used.

Our results have shown how the topical application of 1 ml/day of a solution containing cetirizine 1% is responsible for a significant improvement of the initial framework of AGA. Further studies are needed to better investigate the role of cetirizine in AGA, starting from the current first observation.

Disclosure statement

None declared.

Funding

None declared.

References